Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02000050
Other study ID # IRST154.01
Secondary ID 2013-000770-30
Status Completed
Phase Phase 2
First received
Last updated
Start date October 11, 2013
Est. completion date March 31, 2019

Study information

Verified date June 2023
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase II study of up-front chemotherapy and neo-adjuvant shortcourse radiotherapy for resectable rectal carcinoma. Study Design: Phase II, open-label, single-arm, multi-centre study. STUDY PRODUCT,DOSE,ROUTE,REGIMEN AND DURATION OF ADMINISTRATION: 1. Neoadjuvant Treatment (pre-operative chemo-radiotherapy regimen): FOLFOX4* 2 cycles (WK1+WK3) - Tomotherapy** (WK5) - FOLFOX4* 2 cycles (WK7+WK9) * Oxaliplatin 85 mg/m2 iv: day 1 Levofolinate 100 mg/m2 iv: day 1-2 5-fluorouracil 400 mg/m2 iv in bolus and 600 mg/m2 iv infusion over 22h: day 1-2 Every cycle will last 2 weeks (approximately 48 hours of treatment infusion and 12 days of rest). ** 25 Gy in 5 consecutive fractions, one fraction per day in 5 days on CTV (Clinical Target Volume) at the isodose of the 95% of the total dose. The treatment plan will be elaborated at the work-station dedicated to the Helicoidal Tomotherapy. The treatment could be planned also with linear accelerator with IGRT-IMRT technique or VMAT technique. 2. Restaging (week 11) 3. Surgery (week 12-16) with Total Mesorectal Excision (TME) 4. End Of Treatment (week 16-32) 5. Adjuvant therapy (The maximum interval between surgery and start of adjuvant therapy should be 8 weeks): 6. FOLFOX4* 8 cycles (every 2 weeks) Study Duration: about 5 years. Enrollment period: 36 months. Treatment period: about 8 months. Follow-up: 1 year. NUMBER OF SUBJECTs: · Step A: a maximum of 6 patients. 6 evaluable patients are needed to assess toxicity. If 1 toxicity resulting in discontinuation of treatment will be observed in 6 patients, the treatment can be considered safe (with a confidence > 90%). If 2 or more toxicity resulting in discontinuation of treatment on 6 patients, the study will be stopped because not safe and another type of radiotherapy schedule must be designed. · Step B: a total of 50 patients is required to be recruited in 2 years (including patients enrolled in Step A). The goal is to achieve a proportion of at least 15% of patients with a complete pathological response with the new radiochemotherapeutic treatment.


Description:

Title: Phase II study of up-front chemotherapy and neo-adjuvant shortcourse radiotherapy for resectable rectal carcinoma. Short Title/Acronym: COLORE Protocol Code: IRST154.01 Phase: 2 Study Design: Phase II, open-label, single-arm, multi-centre study. STUDY PRODUCT,DOSE,ROUTE,REGIMEN AND DURATION OF ADMINISTRATION: 1. Neoadjuvant Treatment (pre-operative chemo-radiotherapy regimen): FOLFOX4* 2 cycles (WK1+WK3) - Tomotherapy** (WK5) - FOLFOX4* 2 cycles (WK7+WK9) * Oxaliplatin 85 mg/m2 iv: day 1 Levofolinate 100 mg/m2 iv: day 1-2 5-fluorouracil 400 mg/m2 iv in bolus and 600 mg/m2 iv infusion over 22h: day 1-2 Every cycle will last 2 weeks (approximately 48 hours of treatment infusion and 12 days of rest). ** 25 Gy in 5 consecutive fractions, one fraction per day in 5 days on CTV (Clinical Target Volume) at the isodose of the 95% of the total dose. The treatment plan will be elaborated at the work-station dedicated to the Helicoidal Tomotherapy. The treatment could be planned also with linear accelerator with IGRT-IMRT technique or VMAT technique. 2. Restaging (week 11) 3. Surgery (week 12-16) with Total Mesorectal Excision (TME) 4. End Of Treatment (week 16-32) 5. Adjuvant therapy (The maximum interval between surgery and start of adjuvant therapy should be 8 weeks): 6. FOLFOX4* 8 cycles (every 2 weeks) Study Duration: about 5 years. Enrollment period: 36 months. Treatment period: about 8 months. Follow-up: 1 year. OBJECTIVES Primary objectives: Step A: to evaluate the feasibility and safety of the chemoradiotherapy regimen. Step B: to evaluate the proportion of patients with pathological complete remission after combined radio-chemotherapy. Secondary objectives (of Step B): - To evaluate the safety of the neo-adjuvant treatment - To determine pathological down-staging - To evaluate the rate of R0 resection - To evaluate the sphincter saving resection rate - To evaluate median disease free survival and overall survival - To evaluate the correlation between biomarker, pathological response and outcome (auxiliary\subsidiary Biological Study) NUMBER OF SUBJECT: · Step A: a maximum of 6 patients. 6 evaluable patients are needed to assess toxicity. If 1 toxicity resulting in discontinuation of treatment will be observed in 6 patients, the treatment can be considered safe (with a confidence > 90%). If 2 or more toxicity resulting in discontinuation of treatment on 6 patients, the study will be stopped because not safe and another type of radiotherapy schedule must be designed. · Step B: a total of 50 patients is required to be recruited in 2 years (including patients enrolled in Step A). The goal is to achieve a proportion of at least 15% of patients with a complete pathological response with the new radiochemotherapeutic treatment. STATISTICAL METHODOLOGY: The primary analysis will be performed on the ITT (Intention-To-Treat) population, while the secondary analysis will be conducted on the PP (Per Protocol) population. The number and percentage of treated patients undergoing grade 1 to 4 adverse events (CTC-AE, version 4.0) will be tabulated in the ITT and PP population. No statistical inference will be performed. Step A: Patients, tumor characteristics and toxicity events observed will be described. Step B: The proportion of patients with pathological Complete Response will be calculated. Safety profile will be analyzed. OS (Overall Survival) and DFS (Disease Free Survival) will be estimated with Kaplan-Meier method (Kaplan El, Meier P., J Am Stat Assoc 1958). No interim analysis will be performed. The 95% confidence intervals should also be provided.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date March 31, 2019
Est. primary completion date March 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patients with histologically or cytologically confirmed diagnosis of adenocarcinoma of the mid-low rectum (within 12 cm from the anal verge) 2. Stage: lowT2N0, T2N+M0, T3-4 N-/+M0 (N+ = = 3 nodes >0,5 cm diameter or = 1 nodes > 1 cm diameter) 3. Age =18 and = 80 years 4. ECOG performance status 0-1 5. Patients must have normal organ and marrow function as defined below: 1. - Leukocytes = 3,000/mL 2. - Absolute neutrophil count = 1,500/mL 3. - Platelets = 100,000/mL 4. - Total bilirubin = 1.5 X ULN 5. - AST (SGOT)/ALT (SGPT) = 2.5 X ULN 6. - Creatinine = 1.5 X ULN 6. Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter 7. Participant is willing and able to give informed consent for participation in the study. Exclusion Criteria: 1. Metastatic disease 2. Patients who have had any chemotherapy or radiotherapy prior to entering the study 3. Acute or sub-acute gastrointestinal occlusion 4. Participation in another clinical trial, with any investigational agent within 30 days prior the study screening 5. Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma, superficial bladder tumor and in situ carcinoma of the uterine cervix) 6. History of allergic reactions attributed to compounds of similar chemical or biological composition to drugs used in the study 7. Uncontrolled concomitant illness, including but not limited to: ongoing or active infections; congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance to study requirements

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FOLFOX4
FOLFOX4
Radiation:
Tomotherapy
Tomotherapy
Procedure:
TME (Total Mesorectal Excision)
TME (Total Mesorectal Excision)

Locations

Country Name City State
Italy UO Oncologia Medica IRCCS IRST Meldola FC
Italy Oncologia Medica PO RAVENNA; FAENZA; LUGO Ravenna RA

Sponsors (1)

Lead Sponsor Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Passardi A, Rapposelli IG, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Avanzolini A, Cavaliere D, Rudnas B, Valgiusti M, Barone D, Ferroni F, Frassineti GL, Romeo A. Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity events 6 evaluable patients are needed to assess toxicity. If one toxicity resulting in discontinuation of treatment will be observed in 6 patients, we can conclude that the true probability of toxicity is less than 45% with a confidence >90% and the treatment can be considered safe. If 2 or more toxicity resulting in discontinuation of treatment on 6 patients we can conclude that the true probability of toxicity is greater than 10% with a confidence >90%, and the study will be stopped because not safe and another type of radiotherapy schedule must be designed. 15 months
Primary The Simon optimal two-stage design (Richard Simon, Controlled Clinical Trials 1989) It's a two-stage design that use for P1(the proportion of pCR with the new radio-chemotherapeutic treatment) - P0 (the expected proportion of pCR) =0.15. It's used to understand if a treatment is active or not. 15 months
Primary Complete pathological response (pCR) According to pathological response criteria, a total regression is considered a complete response. This parameter is used to understand if a treatment is active or not ( if at least 7 patients out of 50 enrolled will achieve a pCR, the treatment could be considered active). 3 years
Secondary Objective tumor response rate (ORR) It is the proportion of the intention-to-treat (ITT) population showing a complete or partial response, if confirmed = 4 weeks later.
It will be assessed using RECIST (Response Evaluation Criteria in Solid Tumors) criteria.
5 years
Secondary Pathological Downstaging Rate The proportion of subjects with an improved histopathological response by one or more grade relative to baseline following rectal surgery with Total Mesorectal Excision (TME). 5 years
Secondary Disease-free survival time (DFS) The time from enrolment date to date of first observed progression, relapse or death. 5 years
Secondary Overall survival time (OS) Time from enrolment to the date of death. 5 years
Secondary Intention-to-treat (ITT) population The population of all enrolled patients with baseline assessment of disease, receiving 2 cycles of treatment of FOLFOX4 and at least 1 day of radiotherapy. 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01227239 - Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting Phase 1/Phase 2
Recruiting NCT01459328 - Resource-Sparing Curative Treatment for Rectal Cancer Phase 3
Recruiting NCT04078828 - PR in Endoscopic LAR for Rectal Cancer N/A
Not yet recruiting NCT06424522 - A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients Early Phase 1
Terminated NCT02797405 - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay N/A
Completed NCT01751516 - PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
Terminated NCT01111292 - Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia Phase 1/Phase 2
Completed NCT00682786 - Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma Phase 2
Recruiting NCT04749108 - Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Phase 2/Phase 3
Active, not recruiting NCT01696981 - Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial) N/A
Active, not recruiting NCT01899547 - Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum N/A
Completed NCT01333709 - Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma Phase 2
Recruiting NCT04848311 - Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253 N/A
Not yet recruiting NCT02770911 - Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer Phase 3
Active, not recruiting NCT02432963 - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Phase 1
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Completed NCT01372007 - Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma Phase 3
Active, not recruiting NCT02817126 - Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer N/A
Completed NCT02551237 - Neoadjuvant Treatment for Advanced Rectal Carcinoma Phase 3
Active, not recruiting NCT04713618 - Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy